The efficacy of microsatellite markers and K-ras gene mutations in EUS–FNA samples from patients with benign lesions and pancreatic tumours was demonstrated by a study by Khalid et al. [32]. The gene discussed is KRAS; the disease is pancreatic neoplasm.